Topical Clascoterone Evidence Revisited in 2026: Who Was Studied and Who Was Not for Teens With Inflammatory Acne

Topical clascoterone cream 1% (Winlevi) blocks androgen receptors in skin and was studied in teens 12 and older with moderate-to-severe facial inflammatory acne. It was not tested for efficacy in children under 12, teens with severe nodular disease, or pregnant or nursing teens. The FDA approved it for acne vulgaris in patients 12 years and older in August 2020, according to the FDA approval announcement from BioSpace. Approval rested on two identical 12-week phase 3 trials in 1,440 patients aged 9 and older who applied cream twice daily.

Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.

What did the main trials measure?
Which teens matched the study group?
Which teens were not tested?
What safety points matter for teen use?
What did longer use show?

What did the main trials measure?

The two phase 3 randomized vehicle-controlled trials enrolled patients with moderate-to-severe facial acne vulgaris. Treatment lasted 12 weeks with twice-daily application to the face. Inflammatory and noninflammatory lesion counts and treatment success drove the results.

In the FDA-label group aged 12 and older, with 1,421 patients, clascoterone beat vehicle for treatment success. Success meant clear or almost clear plus a two-grade improvement, at 19.9% versus 7.7%, as reported in the Journal of Drugs in Dermatology in the efficacy analysis in patients 12 and older. Inflammatory lesions fell by 19.7 versus 14.0 with vehicle, and noninflammatory lesions also improved.

Which teens matched the study group?

The teen evidence fits moderate inflammatory acne of the face, not every type of breakout. Trial patients had moderate-to-severe facial acne vulgaris with both red, tender bumps and clogged pores.

They followed a twice-daily cream routine for 12 weeks. A quick check helps families compare: If a teen matches that pattern, the trial results apply most directly. If acne is mostly on the chest or back, or is very severe and nodular, the main trials offer less guidance.

Age 12 or older
Moderate-to-severe facial acne vulgaris
Inflammatory lesions present, plus noninflammatory lesions
Able to use cream twice daily as directed

Which teens were not tested?

Teens with more than 2 facial nodules, nodulocystic acne, or other interfering skin disease were excluded. Medical Bag summarized this exclusion in its report of the Journal of Drugs in Dermatology analysis. Severe nodular disease therefore has no direct efficacy result from those trials.

Children under 12 were enrolled in small numbers, but safety and effectiveness are not established below age 12. The FDA reviewer recommended limiting approval to 12 and older after an HPA-axis-suppression imbalance in subjects aged 9 to under 12. Pregnant or nursing teens also sit outside the efficacy evidence, since Sun Pharma safety information notes no available human pregnancy data, animal findings of fetal harm, and unknown excretion in breast milk.

What safety points matter for teen use?

The label warns about suppression of the HPA axis, the system linking the brain, pituitary, and adrenal glands. NLM DailyMed describes findings at day 14 in the Winlevi label in 1 of 20 adults and 2 of 22 adolescents, with recovery after stopping. It also notes higher susceptibility in children.

For families, this means use the cream exactly as prescribed and do not add extra steroids or hormone creams unless the prescriber knows. Report unusual fatigue, weakness, nausea, very dry skin, stretch marks, or slow healing during or after treatment. A dermatologist can decide whether a pause, an exam, or lab testing fits the symptoms.

What did longer use show?

A multicenter open-label extension treated phase 3 completers aged 12 and older for up to 9 more months. Dosing stayed twice daily, with optional use on the trunk. Response appeared sustained and no new safety signals emerged, according to the Healio report of the Eichenfield extension study.

That extension had no vehicle group and efficacy was not its primary aim. It supports longer safety observation rather than proving stronger clearing over time. Bring photos of baseline breakouts, a list of past acne products, and notes on nodules or cysts to help the dermatologist judge fit.